284 related articles for article (PubMed ID: 10162943)
41. Protease inhibitors in children: combination therapy reduced death by two thirds.
James JS
AIDS Treat News; 2001 Nov; (374):4-5. PubMed ID: 11775935
[No Abstract] [Full Text] [Related]
42. [Antiviral therapy: when to begin, which goals should be set, what must be kept in mind? Tips for nonspecialists].
Jablonowski H
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():10-1. PubMed ID: 16385862
[No Abstract] [Full Text] [Related]
43. When to start therapy--and what to start with.
Gallant JE
Posit Aware; 1997; 8(1):22-3. PubMed ID: 11364093
[TBL] [Abstract][Full Text] [Related]
44. [Enduringly effective and tolerable initial therapy of HIV. Even after 5 years no resistance].
MMW Fortschr Med; 2003 Dec; 145(50):60-1. PubMed ID: 14963980
[No Abstract] [Full Text] [Related]
45. Anti-HIV drug update.
Proj Inf Perspect; 2000 Aug; (30):5-6. PubMed ID: 12171015
[TBL] [Abstract][Full Text] [Related]
46. HIV treatment options.
Smith D
AIDS Treat News; 1998 May; (No 294):4-5. PubMed ID: 11365404
[TBL] [Abstract][Full Text] [Related]
47. The best news yet: AIDS in 1997.
Leccese C
Adv Nurse Pract; 1997 Dec; 5(12):24-30. PubMed ID: 9460014
[No Abstract] [Full Text] [Related]
48. Standard treatments for HIV, Spring 1997.
Smith D
AIDS Treat News; 1997 Apr; (No 269):4-5. PubMed ID: 11364255
[TBL] [Abstract][Full Text] [Related]
49. Four-drug regimens may be better.
AIDS Patient Care STDS; 2000 Dec; 14(12):671. PubMed ID: 11119435
[No Abstract] [Full Text] [Related]
50. [Non-nucleoside reverse transcriptase inhibitor as a fully viable alternative. Strong therapy start without protease inhibitor].
MMW Fortschr Med; 2000 Mar; 142 Suppl 1():30-3. PubMed ID: 10863307
[No Abstract] [Full Text] [Related]
51. ACTG 320 trial halted as three-drug arm proves superior.
AIDS Patient Care STDS; 1997 Jun; 11(3):194. PubMed ID: 11361796
[No Abstract] [Full Text] [Related]
52. [Synthetic HIV proteinase inhibitors and new prospects for drug therapy of HIV infections and AIDS].
Galegov GA
Vopr Virusol; 1997; 42(6):284-6. PubMed ID: 9499245
[No Abstract] [Full Text] [Related]
53. Antiretroviral rounds. Putting resistance to work.
Daar ES; Elion R
AIDS Clin Care; 2004 Jul; 16(7):56, 60. PubMed ID: 15300926
[No Abstract] [Full Text] [Related]
54. AIDS trials ethics questioned.
Cohen J
Science; 1997 Apr; 276(5312):520-3. PubMed ID: 9148404
[No Abstract] [Full Text] [Related]
55. [New AIDS study confirms: triple combination therapy with the protease inhibitor indinavir lowers the risk of mortality by 50%].
Praxis (Bern 1994); 1997 May; 86(20):860. PubMed ID: 9312815
[No Abstract] [Full Text] [Related]
56. ICAAC eyes PIs, NNRTIs, and STIs.
Mascolini M
IAPAC Mon; 2000 Dec; 6(12):362-75. PubMed ID: 11299547
[No Abstract] [Full Text] [Related]
57. Risk of new AIDS diseases in people on triple therapy.
Miller V; Staszewski S; Nisius G; Lepri AC; Sabin C; Phillips AN
Lancet; 1999 Feb; 353(9151):463. PubMed ID: 9989719
[No Abstract] [Full Text] [Related]
58. Switching meds: from protease inhibitors to non-nukes.
TreatmentUpdate; 2001; 12(10):1-2. PubMed ID: 11570061
[No Abstract] [Full Text] [Related]
59. Major controversies in the DHHS guidelines for use of antiretroviral agents in HIV-infected adults. Department of Health and Human Services.
Bartlett JG
Hopkins HIV Rep; 1998 Jan; 10(1):4, 7. PubMed ID: 11365133
[TBL] [Abstract][Full Text] [Related]
60. A new era in HIV care.
Soloway B
Am Fam Physician; 1997 Jul; 56(1):37, 40-2. PubMed ID: 9225661
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
